Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Six Month, Open-label Outpatient, Parallel Group Trial Assessing The Impact Of Inhaled Insulin (Exubera(Registered)) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On Two Oral Anti-diabetic Agents

NCT00282971 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00282971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00282971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Six Month, Open-label Outpatient, Parallel Group Trial Assessing The Impact Of Inhaled Insulin (Exubera(Registered)) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On Two Oral Anti-diabetic Agents
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
March 6, 2006
Completion date
February 19, 2008
Enrollment
354 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2